Business
Pipeline
| Pipeline | Potential Indication |
In-house /Partnership |
2018 | 2019 | 2020 |
| ADC |
Breast Cancer |
In-house |
Optimization (Linker stability, in-vitro efficacy, Synthesis) |
In Vivo Efficacy / PK |
GLP Tox |
| Undisclosed | Partnership | PoC | Optimization |
In Vivo Efficacy /Toxicity |
|
| Long-acting bio pharmaceuticals | Undisclosed |
In-house |
PoC | Optimization |
In Vivo Efficacy /Toxicity |
| Micelle-CoQ10 | Osteoarthritis | Partnership |
Pre-clinical for IND |
IND / Human study |
|
| Health food / Joint protection |
In-house |
Pre-clinical for filing |
Human study |
*Individual certification |
|
| Sjogren’s syndrome |
In-house |
PoC |
(depending on PoC) |
||
|
Micelle-Lutein |
Health food / eye |
In-house |
PoC |
(depending on PoC) |
|